Objectives Autologous chimeric antigen receptor (CAR) T‐cell therapy of B‐cell
malignancies achieves long‐term disease remission in a high fraction of patients and has …

Introduction: CAR T-cell therapy has revolutionized the treatment of patients with
relapsed/refractory (R/R) acute leukemia, NHL, and multiple myeloma. However, there are …

The great clinical success of chimeric antigen receptor (CAR) T cells has unlocked new
levels of immunotherapy for hematological malignancies. Genetically modifying natural killer …

The administration of ex vivo expanded natural killer (NK) cells as potential antitumor
effector cells appears to be suitable for effector cell-based immunotherapies in high-risk …

Background & Aim The use of engineered primary human natural killer (NK) cells holds
great promise in immuno-oncology due to their demonstrated safety and potent anti-tumor …

In recent decades, a new method of cellular immunotherapy was introduced based on
engineering and empowering the immune effector cells. In this type of immunotherapy, the …

T cells engineered with chimeric antigen receptors (CARs) have revolutionized the field of
cell therapy and changed the paradigm of treatment for many patients with relapsed or …

CAR-NK cells may represent a valuable tool, complementary to CAR-T cells, in adoptive
immunotherapy of leukemia and solid tumors. However, gene transfer to human NK cells is …

The generation of autologous T cells expressing a chimeric antigen receptor (CAR) have
revolutionized the field of adoptive cellular therapy. CAR-T cells directed against CD19 have …

Chimeric antigen receptor (CAR) T cell therapy has been a great success in CD19+
hematological diseases. Natural killer (NK) CAR cells offer an alternative to CAR T cells with …